Filtering by:
Cancer in AdolescentsFacts & Figures 2020 Reports Largest One-year Drop in Cancer Mortality
The death rate from cancer in the US declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop ever recorded, according to annual statistics reporting from the American Cancer Society.
Facts & Figures 2019: US Cancer Death Rate has Dropped 27% in 25 Years
The death rate from cancer in the US has declined steadily over the past 25 years, according to annual statistics reporting from the American Cancer Society.
Adolescent and Young Adult Cancer Survival Rates Increase When Re-evaluated
A new way of looking at the data of adolescents and young adults (AYAs) with cancer shows survival rates among this age group are much better than previously thought.
When Adolescents and Young Adults Get Cancer
When an adolescent or young adult gets cancer, treatment can be challenging. At an age characterized by the beginnings of independence, the increased reliance on parents that accompanies a cancer diagnosis often complicates care.
Facts & Figures 2018: Rate of Deaths From Cancer Continues Decline
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
Could Infections Teach Us How to Make Treatments for Pediatric ALL Even Better?
Alix Seif, MD, MPH, is studying a new type of immunotherapy that could teach the immune system long-term memory. The goal is for the immune system to kill any new leukemia cells for the rest of the child's life.
The Current and Future Promise of Immunotherapy for Childhood Cancers
Immunotherapy offers hope to children with cancer who don't respond to standard treatments. The new drug, Kymriah, is likely only the first to use CAR T-cell therapy, which helps immune cells identify cancer cells and kill them.
FDA Approves CAR T-cell Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)
The US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) for certain children, adolescents, and young adults with a form of acute lymphoblastic leukemia (ALL).
